SlideShare a Scribd company logo
Etiologies of pathological jaundice
1
2
3
Kernicterus ( bilirubin encephalopathy)
• Definition: neurological syndrome resulting
from deposition of indirect bilirubin in the
basal ganglia and brain stem
• Multifactorial→ the precise blood level and
the duration of exposure is not known
4
Clinical features of kernicterus
Acute form
• Phase 1 ( 1st-2nd d): poor sucking, stuper,
hypotonia, seizure
• Phase 2(middle of 1st wk): hypertonia of
extensor muscles, opisthonos, retrocollis,fever
• Phase 3(after 1 wk):hypertonia
5
Chronic form
• 1st year: hypotonia, active deep tendon
reflexes, obligatory tonic neck reflex, delayed
motor skill
• After 1st year:movement
disorder(choreoathetosis,ballismus, tremor),
upward gaize, sensorineural hearing loss
6
Prevention of kernicterus
1. for any neonate with jaundice within 24hrs, serum
bilirubin level should be checked
2. Follow up within 2-3d of discharge for all neonate
discharged earlier than 48hr
3. Recognize the presence of possible risk factor
4. Never underestimate the severity of jaundice by
visual assessment
5. Early initiation of phototherapy in those with elevated
bilirubin
6. Recognize parental concern regarding jaundice, poor
feeding, lethargy
7
Diagnosis of pathological jaundice
History and physical examination
• Time of onset, duration, color, and pattern of jaundice
• Symptoms suggestive of anemia,polycythemia
• Family history
• Maternal blood group and rh
• Perinatal hx (sns&sms of infection, drug)
• Term/premature?
• Me conium passed /not?
• Breast feeding/not?
8
• Hematoma/ bruising
• Nutritional status
• Respiratory destress/not
• Hepato-spleenomegally
• Sns &sms suggestive of sepsis
• Vomiting, lethargy, poor feeding, apnea,
bradycardia, excessive weight loss
• Light colored stool, dark urine
9
Laboratory investigation
• TSB and direct bilirubin level
• Blood type(ABO, Rh)
• Direct antibody test(coombs test)
• Serum albumin
• CBC with differential and smear for RBC
morphology
10
• Reticulocyte count
• ETCO(end tidal carbon monoxide)
• G6PD( Glucose-6-phosphate dehydrogenase)
• Urine for reducing agents
11
Treatment of hyperbilirubinemia
Goal: to prevent neurotoxicity while not
causing harm.
• phototherapy
•Exchange transfusion
12
Phototherapy
• Exposure to high intensity of light in the visible
spectrum
• Maximally in the blue range(420-470nm)
• Broad spectrum(white, blue) and narrow-
spectrum(super blue)
• Photochemical reaction
reversible photo-isomerization
lumirubin-irreversible structural isomer
13
• Factors
light enery emitted in the effective range
distance b/n neonate and the lights
surface area of the exposed skin
the rate of production, metabolism and
excretion
• Imtensive phototherapy
special blue fluorescent tubes
lamp 15-20
fiber optic phototherapy blanket
14
• Not substitute for exchange
transfusion(indicated)
• Monitoring: continuous, turned frequently, serum
bilirubin and hematocrit every 4-8 hr should
continue for at least 24 hr after Rx, skin color is
not reliable.
• Role of iv fluid supplementation- dehydrated pts ,
level neat to exchange
15
16
Complications of phototherapy
• Loose stool, erythematous macular rash,
purpuric rash—transient porphyrinemia
• Overheating, dehydration, hypothermia,
bronze baby syndrome ( dark, grayish-brown
skin discoloration), corneal damage
17
Exchange transfusion
• Indications
if intensive phototherapy fails
if the risk of kernicterus exceeds the risk of pr
if signs of kernicterus are evident
if the TSB is in the range for exchange
18
19
• the total amount of blood exchanged is equal to
2x the neonates blood volume
Weight(kg) x 85 ml/Kg x 2
• 5-20ml/cycle are withdrawn and infused, 45-90
min
• Should remove 85% of infant’s RBC, maternal
antibodies, and exchangeable tissue ind.bilirubin
• Catheter
• Continuation of photherapy-reduces subsequent
exchange transfusion.
20
complications
• Blood( transfusion rxn, metabolic instability,
infection), catheter(vessel perforation),
procedure( hypotension or necrotizing
enterocolitis)
• Late-anemia
21

More Related Content

Similar to patholo jaundice.pptx

Management of HIE-1.pptx
Management of HIE-1.pptxManagement of HIE-1.pptx
Management of HIE-1.pptx
HafsaHussainp
 
approach_to_coma.ppt
approach_to_coma.pptapproach_to_coma.ppt
approach_to_coma.ppt
malisalukman
 
Dr. Surendra SGPGI
Dr. Surendra SGPGIDr. Surendra SGPGI
Dr. Surendra SGPGI
surendra kumar
 
physiology of retina , retina physiology
physiology of retina , retina physiologyphysiology of retina , retina physiology
physiology of retina , retina physiology
preetiagarwal53
 
prion diseases.pptx
prion diseases.pptxprion diseases.pptx
prion diseases.pptx
aditisikarwar2
 
Neonatal seizures , Diagnosis investigation and management
Neonatal seizures , Diagnosis investigation and managementNeonatal seizures , Diagnosis investigation and management
Neonatal seizures , Diagnosis investigation and management
FaridAlam29
 
Surgery diet-epilepsy-9.11
Surgery diet-epilepsy-9.11Surgery diet-epilepsy-9.11
Surgery diet-epilepsy-9.11Cleveland Clinic
 
Surgery diet-epilepsy-9.11
Surgery diet-epilepsy-9.11Surgery diet-epilepsy-9.11
Surgery diet-epilepsy-9.11
Cleveland Clinic
 
malignant hyperthermia
malignant hyperthermiamalignant hyperthermia
malignant hyperthermia
Suvadeep Sen
 
Op poisoning - ICU management.Is it straight forward?
Op poisoning - ICU management.Is it straight forward?Op poisoning - ICU management.Is it straight forward?
Op poisoning - ICU management.Is it straight forward?
Vaidyanathan R
 
Op poisoning ICU management - is it st forward ?
Op poisoning   ICU management - is it st forward ?Op poisoning   ICU management - is it st forward ?
Op poisoning ICU management - is it st forward ?
Vaidyanathan R
 
Acute glomerulonephritis for UGs
Acute glomerulonephritis for UGsAcute glomerulonephritis for UGs
Acute glomerulonephritis for UGs
CSN Vittal
 
Management of advanced parkinson’s disease
Management of advanced parkinson’s diseaseManagement of advanced parkinson’s disease
Management of advanced parkinson’s disease
Ahmed Koriesh
 
Prion diseases
Prion diseasesPrion diseases
Prion diseases
Shahin Hameed
 
Epileptic encephalopathy
Epileptic encephalopathyEpileptic encephalopathy
Epileptic encephalopathy
Sooraj Patil
 
NNHB by dr ankur puri
NNHB by dr ankur puriNNHB by dr ankur puri
NNHB by dr ankur puri
Ankur Puri
 
Neurological complications of OP poisoning.pptx
Neurological complications of OP poisoning.pptxNeurological complications of OP poisoning.pptx
Neurological complications of OP poisoning.pptx
ShubhamMalani7
 

Similar to patholo jaundice.pptx (20)

Management of HIE-1.pptx
Management of HIE-1.pptxManagement of HIE-1.pptx
Management of HIE-1.pptx
 
Neonatal seizures
Neonatal seizuresNeonatal seizures
Neonatal seizures
 
Brain Resuscitation
Brain ResuscitationBrain Resuscitation
Brain Resuscitation
 
approach_to_coma.ppt
approach_to_coma.pptapproach_to_coma.ppt
approach_to_coma.ppt
 
Dr. Surendra SGPGI
Dr. Surendra SGPGIDr. Surendra SGPGI
Dr. Surendra SGPGI
 
physiology of retina , retina physiology
physiology of retina , retina physiologyphysiology of retina , retina physiology
physiology of retina , retina physiology
 
prion diseases.pptx
prion diseases.pptxprion diseases.pptx
prion diseases.pptx
 
Neonatal seizures , Diagnosis investigation and management
Neonatal seizures , Diagnosis investigation and managementNeonatal seizures , Diagnosis investigation and management
Neonatal seizures , Diagnosis investigation and management
 
Surgery diet-epilepsy-9.11
Surgery diet-epilepsy-9.11Surgery diet-epilepsy-9.11
Surgery diet-epilepsy-9.11
 
Surgery diet-epilepsy-9.11
Surgery diet-epilepsy-9.11Surgery diet-epilepsy-9.11
Surgery diet-epilepsy-9.11
 
malignant hyperthermia
malignant hyperthermiamalignant hyperthermia
malignant hyperthermia
 
Op poisoning - ICU management.Is it straight forward?
Op poisoning - ICU management.Is it straight forward?Op poisoning - ICU management.Is it straight forward?
Op poisoning - ICU management.Is it straight forward?
 
Op poisoning ICU management - is it st forward ?
Op poisoning   ICU management - is it st forward ?Op poisoning   ICU management - is it st forward ?
Op poisoning ICU management - is it st forward ?
 
Acute glomerulonephritis for UGs
Acute glomerulonephritis for UGsAcute glomerulonephritis for UGs
Acute glomerulonephritis for UGs
 
Management of advanced parkinson’s disease
Management of advanced parkinson’s diseaseManagement of advanced parkinson’s disease
Management of advanced parkinson’s disease
 
Brain death
Brain deathBrain death
Brain death
 
Prion diseases
Prion diseasesPrion diseases
Prion diseases
 
Epileptic encephalopathy
Epileptic encephalopathyEpileptic encephalopathy
Epileptic encephalopathy
 
NNHB by dr ankur puri
NNHB by dr ankur puriNNHB by dr ankur puri
NNHB by dr ankur puri
 
Neurological complications of OP poisoning.pptx
Neurological complications of OP poisoning.pptxNeurological complications of OP poisoning.pptx
Neurological complications of OP poisoning.pptx
 

More from NatanA7

lymphoma.pptx
lymphoma.pptxlymphoma.pptx
lymphoma.pptx
NatanA7
 
chronic leukemia.pptx
chronic leukemia.pptxchronic leukemia.pptx
chronic leukemia.pptx
NatanA7
 
seminar.pptx
seminar.pptxseminar.pptx
seminar.pptx
NatanA7
 
MELE.INTERN.pptx
MELE.INTERN.pptxMELE.INTERN.pptx
MELE.INTERN.pptx
NatanA7
 
nephrotic syndrome.pptx
nephrotic syndrome.pptxnephrotic syndrome.pptx
nephrotic syndrome.pptx
NatanA7
 
Paraparesis.pptx
Paraparesis.pptxParaparesis.pptx
Paraparesis.pptx
NatanA7
 
wub ACS.pptx
wub  ACS.pptxwub  ACS.pptx
wub ACS.pptx
NatanA7
 
AU AVH lecture note.pptx
AU AVH lecture note.pptxAU AVH lecture note.pptx
AU AVH lecture note.pptx
NatanA7
 
Copy of PERINATAL_ASPHYXIA.pptx
Copy of PERINATAL_ASPHYXIA.pptxCopy of PERINATAL_ASPHYXIA.pptx
Copy of PERINATAL_ASPHYXIA.pptx
NatanA7
 
jaundice-new.ppt
jaundice-new.pptjaundice-new.ppt
jaundice-new.ppt
NatanA7
 
Copy of 2,Neonatal_Jaundice.pptx
Copy of 2,Neonatal_Jaundice.pptxCopy of 2,Neonatal_Jaundice.pptx
Copy of 2,Neonatal_Jaundice.pptx
NatanA7
 
PHYSIOLOGICAL JAUNDICE.ppt
PHYSIOLOGICAL JAUNDICE.pptPHYSIOLOGICAL JAUNDICE.ppt
PHYSIOLOGICAL JAUNDICE.ppt
NatanA7
 
asphyxia.PPT
asphyxia.PPTasphyxia.PPT
asphyxia.PPT
NatanA7
 
Viral hepatitis.pptx
Viral hepatitis.pptxViral hepatitis.pptx
Viral hepatitis.pptx
NatanA7
 
Endex & yas FINAL Report.pptx
Endex & yas FINAL Report.pptxEndex & yas FINAL Report.pptx
Endex & yas FINAL Report.pptx
NatanA7
 
Mgt on HIV.pptx
Mgt on HIV.pptxMgt on HIV.pptx
Mgt on HIV.pptx
NatanA7
 
dyspnea.pptx
dyspnea.pptxdyspnea.pptx
dyspnea.pptx
NatanA7
 
Gastrointestinal system.pptx
Gastrointestinal system.pptxGastrointestinal system.pptx
Gastrointestinal system.pptx
NatanA7
 
Presenter፡negesse e.pptx
Presenter፡negesse e.pptxPresenter፡negesse e.pptx
Presenter፡negesse e.pptx
NatanA7
 
Presenter፡negesse e.pptx
Presenter፡negesse e.pptxPresenter፡negesse e.pptx
Presenter፡negesse e.pptx
NatanA7
 

More from NatanA7 (20)

lymphoma.pptx
lymphoma.pptxlymphoma.pptx
lymphoma.pptx
 
chronic leukemia.pptx
chronic leukemia.pptxchronic leukemia.pptx
chronic leukemia.pptx
 
seminar.pptx
seminar.pptxseminar.pptx
seminar.pptx
 
MELE.INTERN.pptx
MELE.INTERN.pptxMELE.INTERN.pptx
MELE.INTERN.pptx
 
nephrotic syndrome.pptx
nephrotic syndrome.pptxnephrotic syndrome.pptx
nephrotic syndrome.pptx
 
Paraparesis.pptx
Paraparesis.pptxParaparesis.pptx
Paraparesis.pptx
 
wub ACS.pptx
wub  ACS.pptxwub  ACS.pptx
wub ACS.pptx
 
AU AVH lecture note.pptx
AU AVH lecture note.pptxAU AVH lecture note.pptx
AU AVH lecture note.pptx
 
Copy of PERINATAL_ASPHYXIA.pptx
Copy of PERINATAL_ASPHYXIA.pptxCopy of PERINATAL_ASPHYXIA.pptx
Copy of PERINATAL_ASPHYXIA.pptx
 
jaundice-new.ppt
jaundice-new.pptjaundice-new.ppt
jaundice-new.ppt
 
Copy of 2,Neonatal_Jaundice.pptx
Copy of 2,Neonatal_Jaundice.pptxCopy of 2,Neonatal_Jaundice.pptx
Copy of 2,Neonatal_Jaundice.pptx
 
PHYSIOLOGICAL JAUNDICE.ppt
PHYSIOLOGICAL JAUNDICE.pptPHYSIOLOGICAL JAUNDICE.ppt
PHYSIOLOGICAL JAUNDICE.ppt
 
asphyxia.PPT
asphyxia.PPTasphyxia.PPT
asphyxia.PPT
 
Viral hepatitis.pptx
Viral hepatitis.pptxViral hepatitis.pptx
Viral hepatitis.pptx
 
Endex & yas FINAL Report.pptx
Endex & yas FINAL Report.pptxEndex & yas FINAL Report.pptx
Endex & yas FINAL Report.pptx
 
Mgt on HIV.pptx
Mgt on HIV.pptxMgt on HIV.pptx
Mgt on HIV.pptx
 
dyspnea.pptx
dyspnea.pptxdyspnea.pptx
dyspnea.pptx
 
Gastrointestinal system.pptx
Gastrointestinal system.pptxGastrointestinal system.pptx
Gastrointestinal system.pptx
 
Presenter፡negesse e.pptx
Presenter፡negesse e.pptxPresenter፡negesse e.pptx
Presenter፡negesse e.pptx
 
Presenter፡negesse e.pptx
Presenter፡negesse e.pptxPresenter፡negesse e.pptx
Presenter፡negesse e.pptx
 

Recently uploaded

special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
Special education needs
 
Additional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdfAdditional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdf
joachimlavalley1
 
Instructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptxInstructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptx
Jheel Barad
 
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdfUnit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Thiyagu K
 
Language Across the Curriculm LAC B.Ed.
Language Across the  Curriculm LAC B.Ed.Language Across the  Curriculm LAC B.Ed.
Language Across the Curriculm LAC B.Ed.
Atul Kumar Singh
 
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
Nguyen Thanh Tu Collection
 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
Jisc
 
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdfAdversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Po-Chuan Chen
 
Polish students' mobility in the Czech Republic
Polish students' mobility in the Czech RepublicPolish students' mobility in the Czech Republic
Polish students' mobility in the Czech Republic
Anna Sz.
 
Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.
Ashokrao Mane college of Pharmacy Peth-Vadgaon
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
TechSoup
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
Levi Shapiro
 
678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf
CarlosHernanMontoyab2
 
How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...
Jisc
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
EverAndrsGuerraGuerr
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
timhan337
 
Digital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and ResearchDigital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and Research
Vikramjit Singh
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
Jean Carlos Nunes Paixão
 
Embracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic ImperativeEmbracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic Imperative
Peter Windle
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
Celine George
 

Recently uploaded (20)

special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
 
Additional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdfAdditional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdf
 
Instructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptxInstructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptx
 
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdfUnit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdf
 
Language Across the Curriculm LAC B.Ed.
Language Across the  Curriculm LAC B.Ed.Language Across the  Curriculm LAC B.Ed.
Language Across the Curriculm LAC B.Ed.
 
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
 
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdfAdversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
 
Polish students' mobility in the Czech Republic
Polish students' mobility in the Czech RepublicPolish students' mobility in the Czech Republic
Polish students' mobility in the Czech Republic
 
Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
 
678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf
 
How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
 
Digital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and ResearchDigital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and Research
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
 
Embracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic ImperativeEmbracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic Imperative
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
 

patholo jaundice.pptx

  • 2. 2
  • 3. 3
  • 4. Kernicterus ( bilirubin encephalopathy) • Definition: neurological syndrome resulting from deposition of indirect bilirubin in the basal ganglia and brain stem • Multifactorial→ the precise blood level and the duration of exposure is not known 4
  • 5. Clinical features of kernicterus Acute form • Phase 1 ( 1st-2nd d): poor sucking, stuper, hypotonia, seizure • Phase 2(middle of 1st wk): hypertonia of extensor muscles, opisthonos, retrocollis,fever • Phase 3(after 1 wk):hypertonia 5
  • 6. Chronic form • 1st year: hypotonia, active deep tendon reflexes, obligatory tonic neck reflex, delayed motor skill • After 1st year:movement disorder(choreoathetosis,ballismus, tremor), upward gaize, sensorineural hearing loss 6
  • 7. Prevention of kernicterus 1. for any neonate with jaundice within 24hrs, serum bilirubin level should be checked 2. Follow up within 2-3d of discharge for all neonate discharged earlier than 48hr 3. Recognize the presence of possible risk factor 4. Never underestimate the severity of jaundice by visual assessment 5. Early initiation of phototherapy in those with elevated bilirubin 6. Recognize parental concern regarding jaundice, poor feeding, lethargy 7
  • 8. Diagnosis of pathological jaundice History and physical examination • Time of onset, duration, color, and pattern of jaundice • Symptoms suggestive of anemia,polycythemia • Family history • Maternal blood group and rh • Perinatal hx (sns&sms of infection, drug) • Term/premature? • Me conium passed /not? • Breast feeding/not? 8
  • 9. • Hematoma/ bruising • Nutritional status • Respiratory destress/not • Hepato-spleenomegally • Sns &sms suggestive of sepsis • Vomiting, lethargy, poor feeding, apnea, bradycardia, excessive weight loss • Light colored stool, dark urine 9
  • 10. Laboratory investigation • TSB and direct bilirubin level • Blood type(ABO, Rh) • Direct antibody test(coombs test) • Serum albumin • CBC with differential and smear for RBC morphology 10
  • 11. • Reticulocyte count • ETCO(end tidal carbon monoxide) • G6PD( Glucose-6-phosphate dehydrogenase) • Urine for reducing agents 11
  • 12. Treatment of hyperbilirubinemia Goal: to prevent neurotoxicity while not causing harm. • phototherapy •Exchange transfusion 12
  • 13. Phototherapy • Exposure to high intensity of light in the visible spectrum • Maximally in the blue range(420-470nm) • Broad spectrum(white, blue) and narrow- spectrum(super blue) • Photochemical reaction reversible photo-isomerization lumirubin-irreversible structural isomer 13
  • 14. • Factors light enery emitted in the effective range distance b/n neonate and the lights surface area of the exposed skin the rate of production, metabolism and excretion • Imtensive phototherapy special blue fluorescent tubes lamp 15-20 fiber optic phototherapy blanket 14
  • 15. • Not substitute for exchange transfusion(indicated) • Monitoring: continuous, turned frequently, serum bilirubin and hematocrit every 4-8 hr should continue for at least 24 hr after Rx, skin color is not reliable. • Role of iv fluid supplementation- dehydrated pts , level neat to exchange 15
  • 16. 16
  • 17. Complications of phototherapy • Loose stool, erythematous macular rash, purpuric rash—transient porphyrinemia • Overheating, dehydration, hypothermia, bronze baby syndrome ( dark, grayish-brown skin discoloration), corneal damage 17
  • 18. Exchange transfusion • Indications if intensive phototherapy fails if the risk of kernicterus exceeds the risk of pr if signs of kernicterus are evident if the TSB is in the range for exchange 18
  • 19. 19
  • 20. • the total amount of blood exchanged is equal to 2x the neonates blood volume Weight(kg) x 85 ml/Kg x 2 • 5-20ml/cycle are withdrawn and infused, 45-90 min • Should remove 85% of infant’s RBC, maternal antibodies, and exchangeable tissue ind.bilirubin • Catheter • Continuation of photherapy-reduces subsequent exchange transfusion. 20
  • 21. complications • Blood( transfusion rxn, metabolic instability, infection), catheter(vessel perforation), procedure( hypotension or necrotizing enterocolitis) • Late-anemia 21